Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases

In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.

• Publication year

  2017

• Venue

  Respiratory Medicine Case Reports

• Publication date

  2017-07-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rmcr.2017.07.004PMID 28752057PMCID 5519224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

  2017cited by this paper
• Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors.

  2017cited by this paper
• Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

  2017cited by this paper
• First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.

  2017cited by this paper
• Transient thyrotoxicosis during nivolumab treatment.

  2017cited by this paper
• First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer

  2017cited by this paper
• Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

  2017cited by this paper
• Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

  2017cited by this paper
• Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

  2016cited by this paper
• Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab

  2016cited by this paper
• Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.

  2015cited by this paper
• Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.

  2015cited by this paper
• Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.

  2013cited by this paper
• Treatment of non-small cell lung cancer (NSCLC).

  2013cited by this paper
• Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

  2013cited by this paper
• Current state of immunotherapy for non-small cell lung cancer.

  2007cited by this paper

• Cardiovascular Risk Profile of Nivolumab Anti-cancer Therapy

  2025cites this paper
• Modern therapies of nonsmall cell lung cancer

  2023cites this paper
• Immunotherapy for the elderly. Maybe the best option for lung cancer?

  2023cites this paper
• Advances in immune checkpoint inhibitors induced-cardiotoxicity

  2023cites this paper
• Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

  2022cites this paper
• Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

  2022cites this paper
• Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab

  2021influential citation
• Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

  2021cites this paper
• Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.

  2021cites this paper
• Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports

  2021cites this paper
• Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

  2020cites this paper
• Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer

  2020cites this paper
• Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis

  2020cites this paper
• Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

  2020cites this paper
• Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods

  2019cites this paper
• Pericardial effusion under nivolumab: case-reports and review of the literature

  2019cites this paper
• Inhaled chemotherapy adverse effects: mechanisms and protection methods

  2019cites this paper
• Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study

  2019cites this paper
• The clinical application of fruquintinib on colorectal cancer

  2019cites this paper
• PD1 – PDL1 Blockade Immunotherapy Applied as a Lung Cancer Treatment: Main Results, Proven Impact and Recent Knowledge Extensions

  2018cites this paper
• Management of adverse events related to checkpoint inhibition therapy

  2018cites this paper
• Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.

  2018cites this paper
• Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.

  2018cites this paper
• PD 1 – PDL 1 Blockade Immunotherapy applied as a Lung Cancer Treatment : Main Results , Proven Impact and Recent Knowledge Extensions 1 MedDocs eBooks

  2018cites this paper
• Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

  2017cites this paper
• Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer

  2017cites this paper
• Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

  2017cites this paper